Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    David Piccioni

    TitleAssistant Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentNeurosciences
    Address9500 Gilman Drive #0819
    CA La Jolla 92093
    Phone858-822-6346
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Akers JC, Hua W, Li H, Ramakrishnan V, Yang Z, Quan K, Zhu W, Li J, Figueroa J, Hirshman BR, Miller B, Piccioni D, Ringel F, Komotar R, Messer K, Galasko DR, Hochberg F, Mao Y, Carter BS, Chen CC. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget. 2017 Jun 01. PMID: 28611312.
        View in: PubMed
      2. Krishnan AP, Karunamuni R, Leyden KM, Seibert TM, Delfanti RL, Kuperman JM, Bartsch H, Elbe P, Srikant A, Dale AM, Kesari S, Piccioni D, Hattangadi-Gluth JA, Farid N, McDonald CR, White NS. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. AJNR Am J Neuroradiol. 2017 May; 38(5):882-889. PMID: 28279985.
        View in: PubMed
      3. Pretanvil JA, Salinas IQ, Piccioni D. Glioblastoma in the elderly: treatment patterns and survival. CNS Oncol. 2016 Dec 21. PMID: 28001088.
        View in: PubMed
      4. Schwaederle M, Husain H, Fanta PT, Piccioni D, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. PMID: 27185373.
        View in: PubMed
      5. McDonald CR, Delfanti RL, Krishnan AP, Leyden KM, Hattangadi-Gluth JA, Seibert TM, Karunamuni R, Elbe P, Kuperman JM, Bartsch H, Piccioni D, White NS, Dale AM, Farid N. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. Neuro Oncol. 2016 Apr 21. PMID: 27106406.
        View in: PubMed
      6. Schwaederle M, Husain H, Fanta PT, Piccioni D, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 1; 7(9):9707-17. PMID: 26848768.
        View in: PubMed
      7. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni D, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 Apr; 15(4):743-52. PMID: 26873727.
        View in: PubMed
      8. Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni D, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244. Am J Clin Oncol. 2015 Dec 09. PMID: 26658237.
        View in: PubMed
      9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni D, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953.
        View in: PubMed
      10. Panella L, Piccioni D, Borcescu L, Isella C, Callegari C. [A MULTIDISCIPLINARY BIOPSYCHOSOCIAL INTEGRATED APPROACH IN ORGANIZATION OF REHABILITATIVE ACTIVITY IN NURSING HOMES (RSA)]. G Ital Med Lav Ergon. 2015 Oct-Dec; 37(4):255-9. PMID: 26934811.
        View in: PubMed
      11. Saria MG, Piccioni D, Carter J, Orosco H, Turpin T, Kesari S. Current Perspectives in the Management of Brain Metastases. Clin J Oncol Nurs. 2015 Aug 1; 19(4):475-8. PMID: 26207714.
        View in: PubMed
      12. Alentorn A, Duran-Peña A, Pingle SC, Piccioni D, Idbaih A, Kesari S. Molecular profiling of gliomas: potential therapeutic implications. Expert Rev Anticancer Ther. 2015 Aug; 15(8):955-62. PMID: 26118895.
        View in: PubMed
      13. Schwaederle M, Daniels GA, Piccioni D, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle. 2015 Jun 3; 14(11):1730-7. PMID: 25928476.
        View in: PubMed
      14. Nozawa A, Rivandi AH, Kanematsu M, Hoshi H, Piccioni D, Kesari S, Hoh CK. Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes. Nucl Med Commun. 2015 Jun; 36(6):573-81. PMID: 25714806.
        View in: PubMed
      15. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015 May 7; 1-8. PMID: 25950492.
        View in: PubMed
      16. Schwaederle M, Daniels GA, Piccioni D, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Mol Cancer Ther. 2015 Jun; 14(6):1488-94. PMID: 25852059.
        View in: PubMed
      17. Schwaederlé M, Daniels GA, Piccioni D, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. PMID: 25596748.
        View in: PubMed
      18. Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, Cho YJ, Pingle SC, Crawford JR, Piccioni D, Kesari S. Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget. 2015 Jan 20; 6(2):1157-70. PMID: 25528767.
        View in: PubMed
      19. Piccioni D, Lai A. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. 2014 Oct; 16(10):1427-8. PMID: 25155359.
        View in: PubMed
      20. van Vugt VA, Piccioni D, Brown BD, Brown T, Saria MG, Juarez T, Kesari S. Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. CNS Oncol. 2014 Jul; 3(4):257-65. PMID: 25286037.
        View in: PubMed
      21. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni D, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. PMID: 24942463.
        View in: PubMed
      22. Piccioni D, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. 2014 Jun; 16(6):815-22. PMID: 24627236.
        View in: PubMed
      23. Piccioni D, Kesari S. Clinical trials of viral therapy for malignant gliomas. Expert Rev Anticancer Ther. 2013 Nov; 13(11):1297-305. PMID: 24138481.
        View in: PubMed
      24. Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni D, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst. 2012 Oct 3; 104(19):1458-69. PMID: 22945948.
        View in: PubMed